Investigational Drug Information for Anamorelin
✉ Email this page to a colleague
What is the drug development status for Anamorelin?
Anamorelin is an investigational drug.
There have been 11 clinical trials for Anamorelin.
The most recent clinical trial was a Phase 3 trial, which was initiated on July 1st 2011.
The most common disease conditions in clinical trials are Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, and Cachexia. The leading clinical trial sponsors are Helsinn Therapeutics (U.S.), Inc, Helsinn Healthcare SA, and National Cancer Institute (NCI).
Summary for Anamorelin
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 80 |
| WIPO Patent Applications | 44 |
| Japanese Patent Applications | 24 |
| Clinical Trial Progress | Phase 3 (2011-07-01) |
| Vendors | 54 |
Recent Clinical Trials for Anamorelin
| Title | Sponsor | Phase |
|---|---|---|
| Anamorelin Study for Advanced Pancreatic Cancer | Helsinn Healthcare SA | Phase 2 |
| Anamorelin Study for Advanced Pancreatic Cancer | Quartesian LLC | Phase 2 |
| Anamorelin Study for Advanced Pancreatic Cancer | Lahey Clinic | Phase 2 |
Clinical Trial Summary for Anamorelin
Top disease conditions for Anamorelin
Top clinical trial sponsors for Anamorelin
US Patents for Anamorelin
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
